MedTrace Logo

Evaluation of the Proliferative Activities of Insulin Analogues in Primary Human Tumor Cells

NCT01267461 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2012-08-10

No results posted yet for this study

Summary

Recently the general medical literature has become aware that the use of certain long-acting insulin analogues could potentially increase cancer risk.During the last few years the investigators group generated information of both scientific and clinical relevance on the proliferative and anti-apoptotic actions of insulin analogues. The goal of this project is to evaluate the hypothesis that the proliferative and signalling activities elicited by insulin analogues may have a impact on tumor behavior. In this study the investigators will asses the biological actions of insulin analogs in primary tumor cells of endometrial and colon cancer.

Conditions

Interventions

OTHER

Tissue sample from tumor

Endometrial cancer specimens will be obtained from patients operated and treated at the Gynecologic Oncology Unit at Meir Medical Center. Colon cancer specimens will be obtained from patients that underwent colonoscopy at the Gastrointestinal Department at Meir Medical Center.

Sponsors & Collaborators

  • Tel Aviv University

    collaborator OTHER

  • Meir Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01267461 on ClinicalTrials.gov